-
公开(公告)号：US12077592B2
公开(公告)日：2024-09-03
申请号：US16743188
申请日：2020-01-15
Applicant: Janssen Biotech, Inc.
Inventor： Ricardo Attar , Rajkumar Ganesan , Francois Gaudet , Bradley J. Heidrich , Carmen Baca Jones , John Lee , Yingzhe Li , Sanjaya Singh , Sathya Venkataramani
CPC classification number: C07K16/2866 , A61K9/0019 , A61P35/00 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/74 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33
Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
-
2.发明公开公开(公告)号：US20240343796A1
公开(公告)日：2024-10-17
申请号：US18528157
申请日：2023-12-04
Applicant: Janssen Biotech, Inc.
Inventor： Ricardo Attar , Francois Gaudet , Mark Tornetta , Alexey Teplyakov , Mark Mendonca , Suzanne Edavettal , Kodandaram Pillarisetti , Nathan Majewski , Yingzhe Li , Leopoldo L. Luistro, III , Diana Chin
CPC classification number: C07K16/28 , A61K39/0011 , C07K16/2809 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
-
公开(公告)号：US20200231686A1
公开(公告)日：2020-07-23
申请号：US16743188
申请日：2020-01-15
Applicant: Janssen Biotech, Inc.
Inventor： Ricardo Attar , Rajkumar Ganesan , Francois Gaudet , Bradley J. Heidrich , Carmen Baca Jones , John Lee , Yingzhe Li , Sanjaya Singh , Sathya Venkataramani
Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
-
公开(公告)号：US10662235B2
公开(公告)日：2020-05-26
申请号：US15629090
申请日：2017-06-21
Applicant: Janssen Biotech, Inc.
Inventor： Mark Anderson , Ricardo Attar , Michael Diem , Linus Hyun , Alastair King , Steven Jacobs , Shalom Goldberg , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha
Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
-
5.发明申请公开(公告)号：US20140155326A1
公开(公告)日：2014-06-05
申请号：US14086250
申请日：2013-11-21
Applicant: Janssen Biotech, Inc.
Inventor： Anderson Mark , Ricardo Attar , Michael Diem , Linus Hyun , Steven Jacobs , Alastair King , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha
CPC classification number: C07K14/78 , A61K38/00 , A61K45/06 , A61K2039/505 , C07K14/47 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K2317/31 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2318/20 , C07K2319/70
Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
Abstract translation: 单特异性和双特异性EGFR和/或c-Met FN3结构域分子，编码分子的分离的核苷酸，载体，宿主细胞及其制备方法可用于治疗分子的产生以及疾病和病症的治疗和诊断。
-
Patent Agency Ranking
公开(公告)号：US12018289B2
公开(公告)日：2024-06-25
申请号：US17097458
申请日：2020-11-13
Applicant: Janssen Biotech, Inc.
Inventor： Ricardo Attar , Jason Dehart , Selina Khan , Vinod Krishna , Jenifer Lum , Christian Maine , Barbara Sanders , Manuel Alejandro Sepulveda , Patrick Wilkinson , Roland Zahn
CPC classification number: C12N7/00 , A61K45/06 , C12N15/86 , A61K2039/505 , C12N2750/14111
Abstract: Provided are vaccines, polypeptides and polynucleotides based on mutant CALR and JAK2 sequences, vectors, host cells, viruses, and methods of making and using them. The disclosure also provides methods of inducing an immune response and methods of treating, preventing, reducing a risk of onset or delaying the onset of a clinical condition characterized by an expression of JAK2V617F or CALR exon 9 mutant, or both JAK2V617F and CALR exon 9 mutant, wherein the method comprises a plurality of administrations of any of the compositions comprising polynucleotides, polypeptides or vectors disclosed herein.
-
公开(公告)号：US20200325210A1
公开(公告)日：2020-10-15
申请号：US16840479
申请日：2020-04-06
Applicant: Janssen Biotech, Inc.
Inventor： Mark Anderson , Ricardo Attar , Michael Diem , Shalom Goldberg , Linus Hyun , Steven Jacobs , Alastair King , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha
Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
-
公开(公告)号：US10106620B2
公开(公告)日：2018-10-23
申请号：US15319344
申请日：2015-06-15
Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services , Janssen Biotech, Inc.
Inventor： Richard W. Childs , Maria Berg , Luis Espinoza Calderon , Kate Sasser , Ricardo Attar
Abstract: Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab′)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab′)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.
-
公开(公告)号：US20140155325A1
公开(公告)日：2014-06-05
申请号：US14085340
申请日：2013-11-20
Applicant: Janssen Biotech, Inc.
Inventor： Anderson Mark , Ricardo Attar , Michael Diem , Linus Hyun , Steven Jacobs , Alastair King , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha
CPC classification number: C07K14/78 , A61K38/00 , A61K45/06 , A61K2039/505 , C07K14/47 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K2317/31 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2318/20 , C07K2319/70
Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
-
公开(公告)号：US10954284B2
公开(公告)日：2021-03-23
申请号：US15637276
申请日：2017-06-29
Applicant: Janssen Biotech, Inc.
Inventor： Mark Anderson , Ricardo Attar , Michael Diem , Linus Hyun , Steven Jacobs , Alastair King , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha
Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.017 seconds)
